SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...
This poster describes the use of CRISPR-ready iPSCs, which are engineered to constitutively express Cas9, enabling the rapid generation of high-efficiency gene knockouts and CRISPR screens in a ...